IN2014DN08830A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08830A
IN2014DN08830A IN8830DEN2014A IN2014DN08830A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A IN 8830DEN2014 A IN8830DEN2014 A IN 8830DEN2014A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A
Authority
IN
India
Prior art keywords
eliciting
immune response
compositions
useful
individual
Prior art date
Application number
Other languages
English (en)
Inventor
Richard C Duke
Alex Franzusoff
Aurelia Haller
Thomas H King
Yingnian Lu
Victoria Kelley Hodson
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of IN2014DN08830A publication Critical patent/IN2014DN08830A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN8830DEN2014 2006-02-02 2007-02-02 IN2014DN08830A (instruction)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Publications (1)

Publication Number Publication Date
IN2014DN08830A true IN2014DN08830A (instruction) 2015-07-10

Family

ID=38345897

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8830DEN2014 IN2014DN08830A (instruction) 2006-02-02 2007-02-02

Country Status (14)

Country Link
US (2) US7736642B2 (instruction)
EP (2) EP2468296A3 (instruction)
JP (3) JP5198290B2 (instruction)
KR (2) KR20140029551A (instruction)
CN (2) CN104826102A (instruction)
AU (1) AU2007212076B2 (instruction)
BR (1) BRPI0706913A2 (instruction)
CA (1) CA2638815A1 (instruction)
IL (2) IL193196A (instruction)
IN (1) IN2014DN08830A (instruction)
MX (1) MX2008009929A (instruction)
SG (2) SG169375A1 (instruction)
TW (2) TW200806316A (instruction)
WO (1) WO2007092792A2 (instruction)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
JP4914990B2 (ja) * 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
CN101262883A (zh) * 2005-07-11 2008-09-10 环球免疫公司 引发针对靶向的疗法的逃逸突变体的免疫应答的组合物和方法
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
SG169375A1 (en) * 2006-02-02 2011-03-30 Globeimmune Inc Yeast-based vaccine for inducing an immune response
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
US20100143393A1 (en) * 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
CA2657849A1 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
SI2121013T1 (sl) * 2007-02-02 2015-02-27 Globeimmune, Inc. Postopki za proizvodnjo cepiv na osnovi kvasovk
WO2008115610A1 (en) * 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
CN102458458B (zh) 2009-04-17 2016-11-16 全球免疫股份有限公司 组合免疫疗法组合物和方法
JP2012527232A (ja) * 2009-05-18 2012-11-08 パナセア バイオテック リミテッド 遺伝子組換え改変ワクシニアアンカラウイルス（ｍｖａ）ベースのインフルエンザ万能ワクチン
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US20120015346A1 (en) * 2010-07-08 2012-01-19 New York Medical College Influenza virus detection and diagnosis
CA2813078A1 (en) * 2010-10-04 2012-04-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US9173933B2 (en) * 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
CN103458922B (zh) * 2011-01-31 2017-10-03 纳米医疗公司 诱导对甲型流感病毒的异源亚型免疫反应的重组病毒载体和方法
MA34956B1 (fr) 2011-02-12 2014-03-01 Globeimmune Inc Therapeutique a base de levure pour infection chronique par l'hepatite b
DK2685995T3 (en) 2011-03-17 2017-08-21 Globeimmune Inc IMMUNTERAPEUTIC Yeast BRACHYURY COMPOSITIONS
US20140377295A1 (en) * 2011-05-23 2014-12-25 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
CA2838950C (en) 2011-06-14 2020-10-27 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
EP2721158B1 (en) * 2011-06-20 2017-05-03 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
WO2013025972A1 (en) 2011-08-17 2013-02-21 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
PL2591798T3 (pl) 2011-11-09 2015-04-30 Werner Lubitz Szczepionka do zastosowania w immunoterapii nowotworów
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
EP2929351B1 (en) * 2012-12-10 2019-10-09 The University of Queensland Cell-free biofragment compositions and related systems, devices, and methods
AU2014235120B2 (en) * 2013-03-15 2017-01-05 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-23 as an adjuvant
TWI674108B (zh) 2013-03-19 2019-10-11 美商環球免疫公司 索脊瘤之以酵母菌爲基礎之免疫療法
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
EP3092004A4 (en) * 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
AU2015227226B2 (en) 2014-03-05 2017-10-05 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
EP3129036B1 (en) 2014-04-11 2021-08-11 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
US11020470B2 (en) * 2015-04-13 2021-06-01 The Regents Of The University Of Michigan Virus-like particles
KR102833272B1 (ko) 2015-08-03 2025-07-10 글로브이뮨 변형된 효모-브라큐리 면역치료학적 조성물
JP6956067B2 (ja) * 2015-08-11 2021-10-27 オービス ヘルス ソリューションズ エルエルシー 細菌およびウイルスのワクチン戦略
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
WO2017222619A2 (en) 2016-03-24 2017-12-28 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
AU2018258119B2 (en) 2017-04-24 2021-04-01 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
AU2018388102A1 (en) 2017-12-21 2020-07-16 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
DE102017012109A1 (de) 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
EP3793576A4 (en) * 2018-05-15 2022-04-06 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
WO2020061203A1 (en) 2018-09-21 2020-03-26 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
CN114269374A (zh) * 2019-05-21 2022-04-01 艾斯佩罗疫苗公司 基于酵母的口服疫苗接种
AU2021220188A1 (en) * 2020-02-11 2022-09-08 Cytonus Therapeutics, Inc. Rapid vaccine platform
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
WO2021211691A1 (en) 2020-04-14 2021-10-21 Immunitybio, Inc. Yeast lysate covid-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5962298A (en) * 1994-01-11 1999-10-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU2001268662A1 (en) * 2000-06-23 2002-01-08 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
JP4914990B2 (ja) * 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1766094A4 (en) * 2004-05-18 2009-11-25 Vical Inc INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
BRPI0515332A (pt) * 2004-09-17 2008-07-22 Univ Massachusetts composições e seus usos para deficiências das enzimas lisossÈmicas
SG169375A1 (en) * 2006-02-02 2011-03-30 Globeimmune Inc Yeast-based vaccine for inducing an immune response

Also Published As

Publication number Publication date
WO2007092792A3 (en) 2008-02-28
US20100196411A1 (en) 2010-08-05
KR20140029551A (ko) 2014-03-10
US20080003239A1 (en) 2008-01-03
JP5198290B2 (ja) 2013-05-15
CN101405026B (zh) 2015-04-22
SG10201402236VA (en) 2014-08-28
CA2638815A1 (en) 2007-08-16
IL193196A (en) 2015-01-29
JP2009528987A (ja) 2009-08-13
JP2015038147A (ja) 2015-02-26
EP1988919A4 (en) 2009-06-10
IL193196A0 (en) 2011-08-01
IL232518A0 (en) 2014-06-30
CN101405026A (zh) 2009-04-08
TW200806316A (en) 2008-02-01
BRPI0706913A2 (pt) 2011-04-12
MX2008009929A (es) 2008-10-01
US7736642B2 (en) 2010-06-15
EP2468296A3 (en) 2013-12-04
JP2013075899A (ja) 2013-04-25
CN104826102A (zh) 2015-08-12
AU2007212076A1 (en) 2007-08-16
EP1988919A2 (en) 2008-11-12
KR20080089671A (ko) 2008-10-07
TW201412329A (zh) 2014-04-01
SG169375A1 (en) 2011-03-30
EP2468296A2 (en) 2012-06-27
WO2007092792A2 (en) 2007-08-16
AU2007212076B2 (en) 2012-10-18
KR101492524B1 (ko) 2015-02-12

Similar Documents

Publication Publication Date Title
IN2014DN08830A (instruction)
WO2007024941A3 (en) Polyvalent vaccine
WO2010019262A3 (en) Polyvalent vaccine
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MY149604A (en) C.perfringens alpha toxoid vaccine
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
EP3725328A3 (en) Novel adjuvant compositions
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
ZA201109444B (en) Vaccines against herpes simplex virus type 2:compositions and methods for eliciting an immune response
MX2009006178A (es) Vacuna contra salmonela.
CA2763359C (en) New human rotavirus strains and vaccines
IN2014DN09791A (instruction)
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
WO2009135199A3 (en) Vaccine compositions and methods
HK1211980A1 (en) Multifunctional oral vaccine based on chromosome recombineering
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
GB2444676A (en) Adjuvanted vaccine
WO2011074006A3 (en) Vaccine composition
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof